Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 206 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Teclistamab ESMO Launches Clinical Trials Funding Initiative to Optimise Cancer Care Pathways FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... June 26, 2021 NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable... April 3, 2026 Young Boy Wears Shirt That Says ‘I Will Be Your Friend’... August 12, 2019 Fostering Black leadership in cancer research July 20, 2023 Load more HOT NEWS Breathing Amidst Uncertainty EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin “My Heart Will Always Hurt”: How I Honor My Childhood Best... “World’s Tiniest Baby” Has Been Released From The Hospital
